The Libyan collections in FI (Herbarium Centrale Italicum and Webb Herbarium) and studies on the Libyan Flora by R. Pampanini - Part 2

This work is the continuation of Part 1, published in 2015, and comprises the reconstruction of the original collections of new taxa described by R. Pampanini and other botanists and, where possible, typification of the new names and taxonomical updating. The material studied for the most part concerns Libyan specimens held in the FI and FI-W herbaria but in some case also K, LD, MPU, P, PAD, PAL, ULT. Other material, which Pampanini studied in Florence was subsequently conserved in other herbaria. Specimens belonging to 21 families have been examined, from the Najadaceae to Zygophyllaceae. As well as typification, bibliographical data have been provided for those already typified. In this second part, a total of 113 names have been indexed and 91 typified, taking the names validly published in the entire work to 353, of which 286 are typified. Also on this occasion, we have provided taxonomic updates for each taxon. The Conclusions present a synthetic sum of the taxa still recognised taxonomically (entirely, in new combinations, or with a new status) in recent works on the Flora of N. Africa, in general revisions of various systematic groups, or reconsidered by the authors of this present work. We have also investigated the phyto-geographic origins of the taxa [according to the dominions proposed by Quézel (1978) for N. Africa]. Finally we have very briefly indicated the presence of material of the R. Pampanini collections (for Cyrenaica, together with R. E. G. Pichi Sermolli in 1934) in the most important herbaria. The paragraph "Addenda et Corrigenda" has been added to the final part of the treatise and relates chiefly to taxa omitted from the first part, either on account of new information or as a result of errors which came to light after publication

Classes of depression symptom trajectories in patients with major depression receiving a collaborative care intervention

Purpose Collaborative care is effective in improving symptoms of patients with depression. The aims of this study were to characterize symptom trajectories in patients with major depression during one year of collaborative care and to explore associations between baseline characteristics and symptom trajectories. Methods We conducted a cluster-randomized controlled trial in primary care. The collaborative care intervention comprised case management and behavioral activation. We used the Patient Health Questionnaire-9 (PHQ-9) to assess symptom severity as the primary outcome. Statistical analyses comprised latent growth mixture modeling and a hierarchical binary logistic regression model. Results We included 74 practices and 626 patients (310 intervention and 316 control recipients) at baseline. Based on a minimum of 12 measurement points for each intervention recipient, we identified two latent trajectories, which we labeled \u27fast improvers\u27 (60.5%) and \u27slow improvers\u27 (39.5%). At all measurements after baseline, \u27fast improvers\u27 presented higher PHQ mean values than \u27slow improvers\u27. At baseline, \u27fast improvers\u27 presented fewer physical conditions, higher health-related quality of life, and had made fewer suicide attempts in their history. Conclusions A notable proportion of 39.5% of patients improved only \u27slowly\u27 and probably needed more intense treatment. The third follow-up in month two could well be a sensible time to adjust treatment to support \u27slow improvers\u27. (DIPF/Orig.

European scenarios for future biological invasions

1. Invasive alien species are one of the major threats to global biodiversity, ecosystem integrity, nature's contributions to people and human health. While scenarios about potential future developments have been available for other global change drivers for quite some time, we largely lack an understanding of how biological invasions might unfold in the future across spatial scales. 2. Based on previous work on global invasion scenarios, we developed a workflow to downscale global scenarios to a regional and policy-relevant context. We applied this workflow at the European scale to create four European scenarios of biological invasions until 2050 that consider different environmental, socio-economic and socio-cultural trajectories, namely the European Alien Species Narratives (Eur-ASNs). 3. We compared the Eur-ASNs with their previously published global counterparts (Global-ASNs), assessing changes in 26 scenario variables. This assessment showed a high consistency between global and European scenarios in the logic and assumptions of the scenario variables. However, several discrepancies in scenario variable trends were detected that could be attributed to scale differences. This suggests that the workflow is able to capture scale-dependent differences across scenarios. 4. We also compared the Global- and Eur-ASNs with the widely used Global and European Shared Socioeconomic Pathways (SSPs), a set of scenarios developed in the context of climate change to capture different future socio-economic trends. Our comparison showed considerable divergences in the scenario space occupied by the different scenarios, with overall larger differences between the ASNs and SSPs than across scales (global vs. European) within the scenario initiatives. 5. Given the differences between the ASNs and SSPs, it seems that the SSPs do not adequately capture the scenario space relevant to understanding the complex future of biological invasions. This underlines the importance of developing independent but complementary scenarios focussed on biological invasions. The downscaling workflow we implemented and presented here provides a tool to develop such scenarios across different regions and contexts. This is a major step towards an improved understanding of all major drivers of global change, including biological invasions

A scenario‐guided strategy for the future management of biological invasions

Future dynamics of biological invasions are highly uncertain because they depend on multiple social–ecological drivers. We used a scenario-based approach to explore potential management options for invasive species in Europe. During two workshops involving a multidisciplinary team of experts, we developed a management strategy arranged into 19 goals relating to policy, research, public awareness, and biosecurity. We conceived solutions for achieving these goals under different plausible future scenarios, and identified four interrelated recommendations around which any long-term strategy for managing invasive species can be structured: (1) a European biosecurity regime, (2) a dedicated communication strategy, (3) data standardization and management tools, and (4) a monitoring and assessment system. Finally, we assessed the feasibility of the management strategy and found substantial differences among scenarios. Collectively, our results indicate that it is time for a new strategy for managing biological invasions in Europe, one that is based on a more integrative approach across socioeconomic sectors and countries

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

The rocky road to the upper atmosphere; NASA's quest to create long-term platforms in the stratosphere

A recent program by NASA aims to develop balloons capable of carrying payloads of several tonnes to above 99% of the Earth's atmosphere for up to a hundred days. However, the road to the stratosphere turned out to be much harder and longer than expectedAerospace Engineerin